NASDAQ:KDNY Chinook Therapeutics (KDNY) News Today $23.31 +1.75 (+8.12%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$21.50▼$23.5150-Day Range$18.66▼$23.4252-Week Range$13.84▼$27.44Volume552,400 shsAverage Volume630,687 shsMarket Capitalization$1.56 billionP/E RatioN/ADividend YieldN/APrice Target$35.83 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get Chinook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KDNY and its competitors with MarketBeat's FREE daily newsletter. Email Address KDNY Media Mentions By Week KDNY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KDNY News Sentiment▼0.430.77▲Average Medical News Sentiment KDNY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KDNY Articles This Week▼103▲KDNY Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineChinook Therapeutics, Inc. (NASDAQ:KDNY) Given Average Recommendation of "Buy" by Brokeragesmarketbeat.com - May 29 at 2:17 AMConnor Clark & Lunn Investment Management Ltd. Sells 51,468 Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY)marketbeat.com - May 26 at 8:49 AMBrokers Set Expectations for Chinook Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:KDNY)americanbankingnews.com - May 26 at 2:02 AMSwiss National Bank Acquires 5,200 Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY)marketbeat.com - May 25 at 4:37 AMFY2023 EPS Estimates for Chinook Therapeutics, Inc. (NASDAQ:KDNY) Reduced by Analystmarketbeat.com - May 24 at 6:19 AMAnalysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Chinook Therapeutics (KDNY) and Zoetis (ZTS)markets.businessinsider.com - May 23 at 12:44 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNYbenzinga.com - May 21 at 9:25 PMChinook Shareholder Noticebenzinga.com - May 21 at 11:25 AMVictory Capital Management Inc. Has $30.48 Million Stock Position in Chinook Therapeutics, Inc. (NASDAQ:KDNY)marketbeat.com - May 21 at 5:52 AMChinook Therapeutics: Travere's Pain Is Chinook's Gainseekingalpha.com - May 19 at 2:59 PMChinook Investor Alertbenzinga.com - May 19 at 12:31 AMGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investorsbenzinga.com - May 18 at 2:29 PMChinook Therapeutics (NASDAQ:KDNY) Shares Down 7.8% americanbankingnews.com - May 18 at 7:18 AMINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investorsbenzinga.com - May 17 at 10:20 PMChinook defended at Guggenheim following short reportmsn.com - May 17 at 12:19 PMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmbusinesswire.com - May 17 at 2:18 AMChinook Therapeutics plunges as Muddy Waters alleges it 'systemically manipulated research findings'in.investing.com - May 16 at 4:12 PMMuddy Waters takes short position in drugmaker Chinook - reportreuters.com - May 16 at 4:12 PMFamed Short Seller Muddy Waters Targets Chinook Therapeutics, Points To Drug Data Questionsmarkets.businessinsider.com - May 16 at 4:12 PMChinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Diseasefinance.yahoo.com - May 16 at 10:00 AMChinook Therapeutics, Inc. (NASDAQ:KDNY) Expected to Earn FY2023 Earnings of ($3.19) Per Shareamericanbankingnews.com - May 14 at 3:20 AMWedbush Weighs in on Chinook Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:KDNY)americanbankingnews.com - May 14 at 1:58 AMQ2 2023 EPS Estimates for Chinook Therapeutics, Inc. (NASDAQ:KDNY) Decreased by Analystamericanbankingnews.com - May 14 at 1:58 AMQ1 2024 Earnings Forecast for Chinook Therapeutics, Inc. Issued By Wedbush (NASDAQ:KDNY)americanbankingnews.com - May 13 at 7:04 AMFY2023 Earnings Forecast for Chinook Therapeutics, Inc. (NASDAQ:KDNY) Issued By William Blairmarketbeat.com - May 12 at 9:40 AMSG Americas Securities LLC Has $210,000 Stock Position in Chinook Therapeutics, Inc. (NASDAQ:KDNY)marketbeat.com - May 12 at 4:33 AMRecap: Chinook Therapeutics Q1 Earningsmsn.com - May 12 at 12:52 AMHC Wainwright Increases Chinook Therapeutics (NASDAQ:KDNY) Price Target to $32.00americanbankingnews.com - May 11 at 6:32 AMChinook Therapeutics (KDNY) Receives a Buy from Wedbushmarkets.businessinsider.com - May 10 at 3:39 PMChinook Therapeutics GAAP EPS of -$0.85, revenue of $1.8Mmsn.com - May 9 at 8:25 PMChinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updatesfinance.yahoo.com - May 9 at 8:25 PMChinook Therapeutics, Inc. (NASDAQ:KDNY) Receives $36.86 Average Target Price from Brokeragesamericanbankingnews.com - May 7 at 2:20 AMChinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congressfinance.yahoo.com - May 5 at 6:41 PMChinook Therapeutics, Inc. (NASDAQ:KDNY) Receives Average Recommendation of "Buy" from Analystsmarketbeat.com - May 4 at 2:38 AMCantor Fitzgerald Reiterates Chinook Therapeutics (KDNY) Overweight Recommendationmsn.com - May 3 at 12:57 PMGuggenheim Maintains Chinook Therapeutics (KDNY) Buy Recommendationmsn.com - May 2 at 11:01 AMChinook Therapeutics (NASDAQ:KDNY) PT Lowered to $35.00 at Guggenheimamericanbankingnews.com - May 2 at 7:36 AMFrazier Life Sciences Management L.P. Purchases 80,000 Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY)marketbeat.com - May 1 at 5:21 AMChinook Therapeutics, Inc. (NASDAQ:KDNY) CEO Eric Dobmeier Sells 23,800 Sharesamericanbankingnews.com - April 27 at 6:44 AMUnusual Call Option Trade in Chinook Therapeutics (KDNY) Worth $50.00Kmsn.com - April 24 at 6:15 PMChinook Therapeutics, Inc. (NASDAQ:KDNY) Short Interest Updateamericanbankingnews.com - April 22 at 6:56 AMDavis Jerel Sells 295,808 Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY) Stockamericanbankingnews.com - April 22 at 4:24 AMChinook: CHK-336 Trial Pause Creates Buying Opportunity, All Eyes On IgAN Readoutseekingalpha.com - April 20 at 3:02 AMChinook Therapeutics (NASDAQ:KDNY) Trading Up 3.2%americanbankingnews.com - April 14 at 6:42 AMChinook Therapeutics, Inc. (NASDAQ:KDNY) Given Average Rating of "Buy" by Analystsamericanbankingnews.com - April 14 at 2:20 AMChinook Therapeutics, Inc.: Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directorsfinanznachrichten.de - April 13 at 1:14 PMChinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directorsfinance.yahoo.com - April 13 at 8:13 AMChinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteersfinance.yahoo.com - April 11 at 10:16 AMInvestors push Chinook Therapeutics (NASDAQ:KDNY) 4.2% lower this week, company's increasing losses might be to blameuk.finance.yahoo.com - April 7 at 2:45 PMChinook Therapeutics, Inc. (NASDAQ:KDNY) Insider Andrew James King Sells 5,000 Sharesamericanbankingnews.com - April 6 at 7:54 AM Get Chinook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KDNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VRNA News Today IRWD News Today XNCR News Today GERN News Today DICE News Today ABCL News Today ZNTL News Today AUPH News Today PTGX News Today SNDX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:KDNY) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chinook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.